QGEN Qiagen NV

$QGEN Friday's 6.5% pop to 44.75 wasn't the FDA headline. It was the Betaville "uncooked" alert traders were passing around: at least one potential buyer is in advanced talks to acquire Qiagen at a "realistic premium." The scaffolding is real. Qiagen has had Moelis and Goldman Sachs running a strategic review since March. CTFN said two parties entered formal due diligence in August. The names linked along the way: KKR, EQT, Advent, TPG, Bain. Manager Magazin reported Qiagen wants at least 50 a share. From Friday's close, that's about a 12% premium. Underneath it was a real product beat too: the FDA cleared the QIAstat-Dx gram-negative sepsis panel on Sept 28, completing the bloodstream-infection menu at 33 pathogen targets and 28 resistance markers, all inside an hour. The 2020 precedent: Thermo Fisher walked away from a 43-euro offer when shareholders rebelled. Landing the premium is one thing; getting holders to accept it is another.

Someone wants to buy Qiagen, and traders noticed. A fresh report says takeover talks for the diagnostics giant are heating up, and $QGEN is up 7% today. Mystery buyer, premium pending.

$QGEN volume building crossing moving averages, fundametal good, a no brainer at this price